



Hungary

Recent and planned developments in pharmaceutical policies 2016

Special topic: Pricing and reimbursement policies for biosimilars

D E V E L O P M E N T S	CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
	<i>No changes</i>	<i>No changes</i>
S P E C I A L T O P I C	OTHER CHANGES	
	<ul style="list-style-type: none"> • <i>No changes</i> 	
POLICIES FOR BIOSIMILARS		
<p><i>Pricing and reimbursement of biosimilars:</i></p> <ul style="list-style-type: none"> • <i>Stepped pricing (minus 30% and minus 10% compared to the originator or the first biosimilar)</i> • <i>Biosimilars in the out-patient sector are included into a special internal reference pricing system.</i> • <i>tenders for biological products in the hospital sector</i> <p><i>Demand-side measures related to biosimilars:</i></p> <ul style="list-style-type: none"> • <i>quotas for doctors to prescribe the cheapest biological products</i> • <i>substitution of biological products is not allowed</i> 		